International business and economics TV channel, Nikkei CNBC featured GNI in "Tokyo Market Watch" program, which covers unique venture companies. Dr. Ying Luo (CEO) and Takashi Kataoka (COO) were interviewed about the GNI's strategy which is to

PharmAsia News reported that China might be the third country in the world to have pirfenidone approved for Idiopathic Pulmoary Fibrosis. "In China, IPF is estimated to affect up to about 400,000 to 500,000 patients every year ......Our company